These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25871827)

  • 21. HisAK70: progress towards a vaccine against different forms of leishmaniosis.
    Domínguez-Bernal G; Horcajo P; Orden JA; Ruiz-Santa-Quiteria JA; De La Fuente R; Ordóñez-Gutiérrez L; Martínez-Rodrigo A; Mas A; Carrión J
    Parasit Vectors; 2015 Dec; 8():629. PubMed ID: 26653170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specificity of anti-saliva immune response in mice repeatedly bitten by Phlebotomus sergenti.
    Drahota J; Lipoldová M; Volf P; Rohousová I
    Parasite Immunol; 2009 Dec; 31(12):766-70. PubMed ID: 19891614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.
    Martins VT; Duarte MC; Chávez-Fumagalli MA; Menezes-Souza D; Coelho CS; de Magalhães-Soares DF; Fernandes AP; Soto M; Tavares CA; Coelho EA
    Parasit Vectors; 2015 Jul; 8():363. PubMed ID: 26160291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of candidate chimeric DNA vaccine against tuberculosis and leishmaniasis.
    Dey A; Kumar U; Sharma P; Singh S
    Vaccine; 2009 Aug; 27(37):5152-60. PubMed ID: 19559111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonclinical safety assessment of repeated administration and biodistribution of ChAd3-EBO-Z Ebola candidate vaccine.
    Planty C; Chevalier G; Duclos MÈ; Chalmey C; Thirion-Delalande C; Sobry C; Steff AM; Destexhe E
    J Appl Toxicol; 2020 Jun; 40(6):748-762. PubMed ID: 31965598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells.
    Coler RN; Goto Y; Bogatzki L; Raman V; Reed SG
    Infect Immun; 2007 Sep; 75(9):4648-54. PubMed ID: 17606603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and toxicity of a new formulated Leishmania major preliminary vaccine in animal model Balb/c and small white conventional laboratory mice.
    Latifynia A; Hazrati SM
    Turkiye Parazitol Derg; 2008; 32(2):103-8. PubMed ID: 18645937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
    Sharma A; Madhubala R
    J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
    Chávez-Fumagalli MA; Costa MA; Oliveira DM; Ramírez L; Costa LE; Duarte MC; Martins VT; Oliveira JS; Olortegi CC; Bonay P; Alonso C; Tavares CA; Soto M; Coelho EA
    Microbes Infect; 2010 Nov; 12(12-13):967-77. PubMed ID: 20601076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.
    Liew FY; Singleton A; Cillari E; Howard JG
    J Immunol; 1985 Sep; 135(3):2102-7. PubMed ID: 3160786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
    Russell DG; Alexander J
    J Immunol; 1988 Feb; 140(4):1274-9. PubMed ID: 3257774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine.
    Tozuka M; Oka T; Jounai N; Egawa G; Ishii KJ; Kabashima K; Takeshita F
    J Dermatol Sci; 2016 Apr; 82(1):38-45. PubMed ID: 26674124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
    Vilela Mde C; Gomes DC; Marques-da-Silva Ede A; Serafim TD; Afonso LC; Rezende SA
    Acta Trop; 2007; 104(2-3):133-9. PubMed ID: 17919443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats.
    Juan L; Xiao Z; Song Y; Zhijian Z; Jing J; Kun Y; Yuna H; Dongfa D; Lili D; Liuxin T; Fei L; Nan L; Fang Y; Yuying S; Yongzhi X
    Hum Vaccin Immunother; 2015; 11(12):2777-83. PubMed ID: 26697972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.